# Ticagrelor

**Cat. No.:** HY-10064  
**CAS No.:** 274693-27-5  
**Molecular Formula:** C₂₃H₂₈F₂N₆O₄S  
**Molecular Weight:** 522.57  
**Target:** P2Y Receptor  
**Pathway:** GPCR/G Protein  
**Storage:** -20°C, protect from light, stored under nitrogen

* In solvent: -80°C, 1 years; -20°C, 6 months (protect from light, stored under nitrogen)

## SOLVENT & SOLUBILITY

### In Vitro

DMSO: ≥ 50 mg/mL (95.68 mM)  
* "≥" means soluble, but saturation unknown.

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 mM</td>
<td>1.9136 mL</td>
<td>9.5681 mL</td>
<td>19.1362 mL</td>
</tr>
<tr>
<td></td>
<td>5 mM</td>
<td>0.3827 mL</td>
<td>1.9136 mL</td>
<td>3.8272 mL</td>
</tr>
<tr>
<td></td>
<td>10 mM</td>
<td>0.1914 mL</td>
<td>0.9568 mL</td>
<td>1.9136 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

### In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
   Solubility: ≥ 2 mg/mL (3.83 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
   Solubility: ≥ 2 mg/mL (3.83 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil  
   Solubility: ≥ 2 mg/mL (3.83 mM); Clear solution

## BIOLOGICAL ACTIVITY

### Description

Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.

### IC₅₀ & Target

**IC₅₀** Target: P2Y12 Receptor

**In Vitro**

Ticagrelor promotes a greater inhibition of adenosine 5'-diphosphate (ADP)-induced Ca²⁺ release in isched platelets vs other P2Y12R antagonists. This additional effect of ticagrelor beyond P2Y12R antagonism is in part as a consequence of ticagrelor inhibiting the equilibrative nucleoside transporter 1 (ENT1) on platelets, leading to accumulation of extracellular adenosine.
and activation of Gs-coupled adenosine A2A receptors\(^1\). B16-F10 cells exhibit decreased interaction with platelets from ticagrelor-treated mice compared to saline-treated mice\(^2\).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

<table>
<thead>
<tr>
<th>In Vivo</th>
</tr>
</thead>
<tbody>
<tr>
<td>In B16-F10 melanoma intravenous and intrasplenic metastasis models, mice treated with a clinical dose of ticagrelor (10 mg/kg) exhibits marked reductions in lung (84%) and liver (86%) metastases. Furthermore, ticagrelor treatment improves survival compared to saline-treated animals. A similar effect is observed in a 4T1 breast cancer model, with reductions in lung (55%) and bone marrow (87%) metastases following ticagrelor treatment(^2). Single oral administration of ticagrelor (1-10 mg/kg) causes dose-related inhibitory effect on platelet aggregation. Ticagrelor, at the highest dose (10 mg/kg) significantly inhibits platelet aggregation at 1 h after dosing and the peak inhibition is observed at 4 h after dosing(^3).</td>
</tr>
</tbody>
</table>

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

<table>
<thead>
<tr>
<th>PROTOCOL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Animal Administration</strong>(^3)</td>
</tr>
</tbody>
</table>
| Rats: Prasugrel (10 mg/kg, p.o.) and ticagrelor (30 mg/kg, p.o.), doses that produced similar levels of inhibition of platelet aggregation, are administered to rats 4 h before the bleeding time measurements. Fresh, washed platelets (1 × 10\(^10\) platelets/mL) are prepared from other rats and suspended in Hank’s balanced salt solution. Platelets are transfused via the jugular vein to rats 1 h before the bleeding time measurements and the bleeding time is determined\(^3\).

Mice: Female BALB/c mice are inoculated subcutaneously in the fourth mammary pad with 4T1 breast cancer cells. Once a tumor is palpable, mice receive daily injections of PBS or ticagrelor (10 mg/kg). One week later, mice undergo primary tumor resection. At 28 days mice are sacrificed and lungs, femurs and tibiae harvested. Dissociated cells from lung and bone marrow are plated in medium containing 60 μM 6-thioguanine. After 14 days, culture plates are fixed with methanol and stained with 0.03% methylene blue to enumerate metastatic 4T1 colonies\(^2\). |

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

<table>
<thead>
<tr>
<th>CUSTOMER VALIDATION</th>
</tr>
</thead>
</table>
|  • Curr Biol. 2023 May 6;S0960-9822(23)00529-8.  
  • Biomed Res Int. 2022 Sep 20;2022:8265898.  
  • Research Square Preprint. 2021 Mar. |

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

<table>
<thead>
<tr>
<th>REFERENCES</th>
</tr>
</thead>
</table>